Related references
Note: Only part of the references are listed.Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease
Andreia Teixeira-Castro et al.
BRAIN (2015)
Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism
Andrea de Bartolomeis et al.
CNS DRUGS (2015)
Specific targeting of neurotoxic side effects and pharmacological profile of the novel cancer stem cell drug salinomycin in mice
Wolfgang Boehmerle et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
Presynaptic Calcium Channel Inhibition Underlies CB1 Cannabinoid Receptor-Mediated Suppression of GABA Release
G. Szabo Gergely et al.
JOURNAL OF NEUROSCIENCE (2014)
The Global Epidemiology of Hereditary Ataxia and Spastic Paraplegia: A Systematic Review of Prevalence Studies
Luis Ruano et al.
NEUROEPIDEMIOLOGY (2014)
Chronic Treatment with 17-DMAG Improves Balance and Coordination in A New Mouse Model of Machado-Joseph Disease
Anabela Silva-Fernandes et al.
NEUROTHERAPEUTICS (2014)
Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23
Jessica R. Blount et al.
NATURE COMMUNICATIONS (2014)
Different ataxin-3 amyloid aggregates induce intracellular Ca2+ deregulation by different mechanisms in cerebellar granule cells
Francesca Pellistri et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2013)
Loss of D2 Dopamine Receptor Function Modulates Cocaine-Induced Glutamatergic Synaptic Potentiation in the Ventral Tegmental Area
Anuradha Madhavan et al.
JOURNAL OF NEUROSCIENCE (2013)
Toward RNAi Therapy for the Polyglutamine Disease Machado-Joseph Disease
Maria do Carmo Costa et al.
MOLECULAR THERAPY (2013)
Silencing Mutant ATXN3 Expression Resolves Molecular Phenotypes in SCA3 Transgenic Mice
Edgardo Rodriguez-Lebron et al.
MOLECULAR THERAPY (2013)
H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse
Hung-Li Wang et al.
NEUROPHARMACOLOGY (2013)
Silencing Mutant Ataxin-3 Rescues Motor Deficits and Neuropathology in Machado-Joseph Disease Transgenic Mice
Clevio Nobrega et al.
PLOS ONE (2013)
Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease
Ana T. Simoes et al.
BRAIN (2012)
Toward understanding Machado-Joseph disease
Maria do Carmo Costa et al.
PROGRESS IN NEUROBIOLOGY (2012)
Neurite outgrowth mediated by the heat shock protein Hsp90α: a novel target for the antipsychotic drug aripiprazole
T. Ishima et al.
TRANSLATIONAL PSYCHIATRY (2012)
MScreen: An Integrated Compound Management and High-Throughput Screening Data Storage and Analysis System
Renju T. Jacob et al.
JOURNAL OF BIOMOLECULAR SCREENING (2012)
The Josephin Domain Determines the Morphological and Mechanical Properties of Ataxin-3 Fibrils
Laura Masino et al.
BIOPHYSICAL JOURNAL (2011)
Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease
Isabel Nascimento-Ferreira et al.
BRAIN (2011)
The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability
Thomas M. Durcan et al.
HUMAN MOLECULAR GENETICS (2011)
Neuron-specific proteotoxicity of mutant ataxin-3 in C-elegans: rescue by the DAF-16 and HSF-1 pathways
Andreia Teixeira-Castro et al.
HUMAN MOLECULAR GENETICS (2011)
Early Changes in Cerebellar Physiology Accompany Motor Dysfunction in the Polyglutamine Disease Spinocerebellar Ataxia Type 3
Vikram G. Shakkottai et al.
JOURNAL OF NEUROSCIENCE (2011)
A mitochondrial ubiquitin ligase MITOL controls cell toxicity of polyglutamine-expanded protein
Ayumu Sugiura et al.
MITOCHONDRION (2011)
Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease
Philipp Koch et al.
NATURE (2011)
HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3
An-Hsun Chou et al.
NEUROBIOLOGY OF DISEASE (2011)
Polyglutamine diseases: The special case of ataxin-3 and Machado-Joseph disease
Carlos A. Matos et al.
PROGRESS IN NEUROBIOLOGY (2011)
Balancing act: deubiquitinating enzymes in the nervous system
Sokol V. Todi et al.
TRENDS IN NEUROSCIENCES (2011)
Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3
Fiona M. Menzies et al.
BRAIN (2010)
New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado–Joseph disease)
Udo Rüb et al.
CURRENT OPINION IN NEUROLOGY (2009)
Gp78, an ER associated E3, promotes SOD1 and ataxin-3 degradation
Zheng Ying et al.
HUMAN MOLECULAR GENETICS (2009)
Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects
Mei Han et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2009)
Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability
Umesh K. Jinwal et al.
JOURNAL OF NEUROSCIENCE (2009)
E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation and suppresses polyglutamine protein aggregation and toxicity
Amit Mishra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Deranged Calcium Signaling and Neurodegeneration in Spinocerebellar Ataxia Type 3
Xi Chen et al.
JOURNAL OF NEUROSCIENCE (2008)
Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation
An-Hsun Chou et al.
NEUROBIOLOGY OF DISEASE (2008)
Polyglutarnine neurodegeneration: protein misfolding revisited
Aislinn J. Williams et al.
TRENDS IN NEUROSCIENCES (2008)
CAG repeat disorder models and human neuropathology: similarities and differences
Mitsunori Yamada et al.
ACTA NEUROPATHOLOGICA (2008)
Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination
Ina Schmitt et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Polyglutamine diseases: emerging concepts in pathogenesis and therapy
Jieya Shao et al.
HUMAN MOLECULAR GENETICS (2007)
Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3
Annette Haacke et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Dominantly inherited ataxias: Lessons learned from Machado Joseph disease/spinocerebellar atria type 3
Henry L. Paulson
SEMINARS IN NEUROLOGY (2007)
Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors:: functional receptor-binding and in vivo electrophysiological studies
Arlene D. Stark et al.
PSYCHOPHARMACOLOGY (2007)
The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step
Andrew M. Ellisdon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis
A Boeddrich et al.
EMBO JOURNAL (2006)
Rapamycin alleviates toxicity of different aggregate-prone proteins
Z Berger et al.
HUMAN MOLECULAR GENETICS (2006)
Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: Trapping early oligomers of non-expanded ataxin-3
L Gales et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
Therapeutics development for triplet repeat expansion diseases
NA Di Prospero et al.
NATURE REVIEWS GENETICS (2005)
Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes
NR Jana et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Population genetics of wild-type CAG repeats in the Machado-Joseph disease gene in Portugal
M Lima et al.
HUMAN HEREDITY (2005)
Molecular clearance of ataxin-3 is regulated by a mammalian E4
M Matsumoto et al.
EMBO JOURNAL (2004)
Sharing of polyglutamine localization by the neuronal nucleus and cytoplasm in CAG-repeat diseases
M Yamada et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2004)
Autosomal dominant cerebellar ataxias:: clinical features, genetics, and pathogenesis
L Schöls et al.
LANCET NEUROLOGY (2004)
Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function
YC Tsai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Immunohistochemical study of neuronal intranuclear and cytoplasmic inclusions in Machado-Joseph disease
M Hayashi et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2003)
Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis
YH Chai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit
CK Cemal et al.
HUMAN MOLECULAR GENETICS (2002)
Improvement in the molecular diagnosis of Machado-Joseph disease
P Maciel et al.
ARCHIVES OF NEUROLOGY (2001)
Share Paper
